Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen

Wednesday, Eli Lilly And Co LLY announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer's disease.

Donanemab treatment slowed clinical decline by 35% compared to placebo and resulted in 40% less decline on the ability to perform activities of daily living.

In a small patient population with high tau levels, donanemab demonstrated meaningful positive results across all clinical endpoints, with CDR-SB and iADRS showing a 29% and 22% slowing of decline, respectively.

Raymond James writes that at a high level, efficacy data look overall in line vs. Biogen Inc BIIBEisai Limited's ESALY lecanemab (CDR-SB slowing of 29% vs. 27%).

The analyst views the data as a positive for Biogen, citing success with another AΒ plaque-busting agent validating the approach overall.

It also says that donanemab is more convenient (once monthly vs. q-2wks with lecanemab) and a finite dosing schedule (patients only dosed until AB negative [>50% completed treatment by 12- mos]) offers clear competitive advantages over lecanemab.

Guggenheim Partners writes that these results are a 'huge' step for the class and Alzheimer's field.

The analyst forecasts global donanemab sales of $5.2 billion (risk-adjusted) and $7.4 billion (risk-unadjusted) in 2031E and notes that most biotech products in categories like this trade at 6x peak sales and Eli Lilly also has a potential follow-on subQ product to extend the franchise and portfolio.

Price Action: LLY shares are down 0.70% at $426.17, and BIIB shares are up 0.19% at $311.59 at the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechLarge CapNewsHealth CareAnalyst RatingsTrading IdeasGeneralExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!